Chimeric antigen receptor T-cell therapy hits the market

Immunotherapy. 2018 Aug;10(11):911-912. doi: 10.2217/imt-2018-0075.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adult
  • Antigens, CD19 / immunology
  • Antineoplastic Agents / therapeutic use*
  • Cancer Vaccines / immunology*
  • Child
  • Drug Resistance, Neoplasm
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Leukemia, B-Cell / immunology
  • Leukemia, B-Cell / therapy*
  • Neoplasm Recurrence, Local
  • Receptors, Antigen, T-Cell / therapeutic use*
  • Receptors, Chimeric Antigen / genetics*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation
  • United States
  • United States Food and Drug Administration
  • Young Adult

Substances

  • Antigens, CD19
  • Antineoplastic Agents
  • Cancer Vaccines
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • tisagenlecleucel